Literature DB >> 28095261

Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study.

Yu-Jie Zhou1,2, Hai Zou3, Ji-Na Zheng1,2, Tian-Tian Zou1,4, Alessandro Vitale5, Luca Miele6,7, Sven Van Poucke8, Wen-Yue Liu9, Shengrong Shen10, Dong-Chu Zhang11, Ke-Qing Shi1,12, Ming-Hua Zheng1,12.   

Abstract

BACKGROUND: Several risk factors are able to predict non-alcoholic fatty liver (NAFL) development, but the predictive value of serum alkaline phosphatase (ALP) remains uncertain. Our aim is to investigate the association between serum ALP levels and NAFL.
METHODS: 21,331 NAFL-free subjects were included. Sex-specific ALP quartiles (Q1 to Q4) were defined. With Q1 used as reference, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated across each quartile.
RESULTS: After adjusting for confounding variables, values in Q2, Q3 and Q4 had HRs (95%CIs) of 1.16 (0.94-1.43), 1.38 (1.13-1.69), 1.51 (1.24-1.83) in females and 0.99 (0.90-1.09), 1.04 (0.95-1.14), 0.96 (0.87-1.05) in males, respectively. A subgroup analysis of age factors in females, from Q2 to Q4, adjusted HRs (95%CIs) were 1.31 (0.81-1.99), 1.86 (1.23-2.81), 2.44 (1.60-3.71) in their 30 s, 1.13 (0.83-1.54), 1.17 (0.85-1.62), 1.65 (1.22-2.25) in their 40 s, and 0.95 (0.51-1.78), 0.91 (0.52-1.62), 0.89 (0.53-1.52) in their 50 s.
CONCLUSIONS: Higher serum ALP levels are considered a significant predictor for NAFL development in females aged 30 to 50.

Entities:  

Keywords:  Non-alcoholic fatty liver; age factors; alkaline phosphatase; risk factor; sex factors

Mesh:

Substances:

Year:  2017        PMID: 28095261     DOI: 10.1080/17474124.2017.1283984

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  4 in total

1.  Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK.

Authors:  Lee-Ching Lew; Yan-Yan Hor; Mohamad-Hafis Jaafar; Amy-Sie-Yik Lau; Boon-Kiat Lee; Li-Oon Chuah; Kien-Pong Yap; Azali Azlan; Ghows Azzam; Sy-Bing Choi; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

Review 2.  Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Authors:  Arie Regev; Melissa Palmer; Mark I Avigan; Lara Dimick-Santos; William R Treem; John F Marcinak; Daniel Seekins; Gopal Krishna; Frank A Anania; James W Freston; James H Lewis; Arun J Sanyal; Naga Chalasani
Journal:  Aliment Pharmacol Ther       Date:  2019-02-13       Impact factor: 8.171

3.  Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.

Authors:  Yingying Liu; Yingying Tan; Jiaqi Huang; Chao Wu; Xiaotian Fan; Antony Stalin; Shan Lu; Haojia Wang; Jingyuan Zhang; Fanqin Zhang; Zhishan Wu; Bing Li; Zhihong Huang; Meilin Chen; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

4.  Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial.

Authors:  Kátia Cansanção; Marta Citelli; Nathalie Carvalho Leite; María-Carmen López de Las Hazas; Alberto Dávalos; Maria das Graças Tavares do Carmo; Wilza Arantes Ferreira Peres
Journal:  Nutrients       Date:  2020-11-02       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.